Epitalon · Epithalone · Ala-Glu-Asp-Gly Tetrapeptide
A synthetic tetrapeptide analogue of Epithalamin — the natural peptide produced by the pineal gland. Epithalon is the most extensively researched longevity peptide, with over 40 years of Russian research demonstrating telomerase activation, tumour suppression, melatonin restoration and a documented 1.6–4.1 fold reduction in mortality in a 266-person human cohort study.
Epithalon (also spelled Epitalon) is a synthetic tetrapeptide — Ala-Glu-Asp-Gly — derived from Epithalamin, a natural peptide complex produced by the pineal gland. It was developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, where it has been studied for over 40 years. It represents one of the most extensively researched longevity compounds available, with a body of evidence spanning animal studies, human clinical research and mechanistic investigations that is unmatched in the peptide longevity space.
Epithalon's primary mechanism involves activation of telomerase — the enzyme responsible for maintaining and repairing telomere length. Telomeres are protective caps on chromosomes that shorten with each cell division. When telomeres become critically short, cells enter senescence or die — this process is a fundamental driver of aging. Epithalon activates telomerase in somatic cells, extending telomere length and extending cellular replicative capacity.
Critically, research has shown that in cancer cells Epithalon activates the ALT (Alternative Lengthening of Telomeres) pathway rather than telomerase — meaning it does not provide cancer cells with the telomerase boost that was initially a theoretical concern. This selectivity addresses the primary safety question around telomerase-activating compounds.
The most significant human evidence for Epithalon is a prospective cohort study of 266 people over age 60. The study demonstrated that Epithalamin treatment produced a 1.6–1.8 fold reduction in mortality over 6 years, a 2.5 fold reduction when combined with Thymalin, and a 4.1 fold reduction when combined with Thymalin and administered annually rather than once. These are extraordinary numbers — no intervention in Western longevity research approaches this magnitude of effect in a human cohort.
Epithalon restores pineal gland function — increasing melatonin production that declines with age. This melatonin restoration contributes to improved sleep quality, circadian rhythm regulation and the well-documented anti-cancer properties of melatonin. The pineal-melatonin connection also links Epithalon's effects to immune regulation and antioxidant protection.
Multiple animal studies have demonstrated Epithalon's tumour suppression properties — reducing spontaneous tumour incidence, suppressing HER-2/neu breast cancer development in transgenic mice, and extending lifespan in cancer-prone animal models. These effects operate through immune restoration, melatonin elevation and the ALT telomere mechanism rather than direct cytotoxicity.
The most commonly used protocol based on Khavinson's research is a 10-night course of daily injections, repeated 2-3 times per year. Some researchers use longer courses. The compound is administered SubQ or IM, typically in the evening given its melatonin-related mechanisms.